Moleculin Hits 45 Subject Enrollment Milestone

Moleculin has achieved a significant milestone by enrolling 45 subjects in its pivotal AML trial, triggering the final countdown to its mid-2026 data readout. The company anticipates an imminent unblinding of early blinded results, which could represent a critical juncture in its history. Preliminary blinded data suggests a promising 40% response rate, indicating potential efficacy for its investigational therapy. This progress is a key step towards potentially bringing a new treatment option to patients suffering from acute myeloid leukemia.